Soligenix Inc (SNGX)

Apr 22, 2025

Soligenix (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat - The Globe and Mail

Apr 22, 2025

Apr 15, 2025

Soligenix (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM) - The Globe and Mail

Apr 15, 2025

Apr 15, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ f - GuruFocus

Apr 15, 2025

Apr 14, 2025

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses… - MSN

Apr 14, 2025

Apr 14, 2025

Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma - Nasdaq

Apr 14, 2025

Apr 14, 2025

Soligenix (SNGX) Reports Promising Interim Results for HyBryte i - GuruFocus

Apr 14, 2025

Apr 14, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBrytetm for 18 Weeks - Lelezard

Apr 14, 2025

Apr 14, 2025

Soligenix IncPositive Outcome In 75% Of Ctcl Patients Treated With Hybryte For 18 Weeks - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks - Finansavisen

Apr 14, 2025

Apr 14, 2025

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks (PR Newswire) - Aktiellt

Apr 14, 2025

Apr 09, 2025

Behcet's Disease Market to Show Remarkable Growth Trends from - openPR.com

Apr 09, 2025

Apr 09, 2025

Behcet’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Soligenix, Chugai Pharma, UMC Utrecht, Ganzhou Hemay Pharma, Amgen - The Globe and Mail

Apr 09, 2025

Apr 08, 2025

Soligenix (NASDAQ: SNGX) Spotlighted In Zacks Small-Cap Research Report, Earns $35 Valuation - Barchart.com

Apr 08, 2025

Apr 08, 2025

Soligenix (NASDAQ: SNGX) Spotlighted in Zacks Small-Cap Research Report, Earns $35 Valuation - The Globe and Mail

Apr 08, 2025

Apr 05, 2025

SNGX stock touches 52-week low at $1.74 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

SNGX stock touches 52-week low at $1.74 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

Soligenix (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment - Barchart.com

Apr 03, 2025

Mar 30, 2025

Zacks Small Cap Decreases Earnings Estimates for Soligenix - The AM Reporter

Mar 30, 2025

Mar 28, 2025

Zacks Maintains $35.00 Price Per Share Valuation for Soligenix (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress - Barchart.com

Mar 28, 2025

Mar 28, 2025

Q1 Earnings Forecast for Soligenix Issued By Zacks Small Cap - Defense World

Mar 28, 2025

Mar 26, 2025

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19… - Yahoo Finance

Mar 26, 2025

Mar 25, 2025

CiVax booster shows broad COVID-19 variant protection By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

IBN Initiates Coverage of Soligenix Inc. - GlobeNewswire

Mar 25, 2025

Mar 25, 2025

First National Financial Corporation to Host First Quarter Earnings Call on April 30, 2025 - The Globe and Mail

Mar 25, 2025

Mar 25, 2025

CiVax booster shows broad COVID-19 variant protection - Investing.com

Mar 25, 2025

Mar 25, 2025

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants - PR Newswire

Mar 25, 2025

Mar 24, 2025

Soligenix (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results - The Globe and Mail

Mar 24, 2025

Mar 21, 2025

Soligenix Inc. (SNGX) reports earnings - Quartz

Mar 21, 2025

Mar 21, 2025

SOLIGENIX, INC. SEC 10-K Report - TradingView

Mar 21, 2025

Mar 21, 2025

Soligenix Trumps Year-End Financials - Baystreet.ca

Mar 21, 2025

Mar 21, 2025

Soligenix reports progress and 2024 financials By Investing.com - Investing.com Australia

Mar 21, 2025

Mar 21, 2025

Soligenix reports progress and 2024 financials - Investing.com India

Mar 21, 2025

Mar 21, 2025

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results - Quantisnow

Mar 21, 2025

Mar 21, 2025

Soligenix Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 21, 2025

Mar 21, 2025

Soligenix Financial Results Reveal Widening Losses While Clinical Pipeline Expands - StockTitan

Mar 21, 2025

Mar 19, 2025

Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail

Mar 19, 2025

Mar 19, 2025

Soligenix (SNGX) Expected to Announce Earnings on Friday - The AM Reporter

Mar 19, 2025

Mar 14, 2025

Soligenix Inc expected to post a loss of 95 cents a shareEarnings Preview - TradingView

Mar 14, 2025

Mar 14, 2025

Soligenix (SNGX) Projected to Post Earnings on Friday - Defense World

Mar 14, 2025

Mar 13, 2025

Soligenix (NASDAQ: SNGX) Is ‘One to Watch’ - The Globe and Mail

Mar 13, 2025

Mar 13, 2025

Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’ - Financial Content

Mar 13, 2025

Mar 09, 2025

AllPennyStocks.com News: A Steady Stream of News and Developments Pushes Soligenix Near 52 Week High - ACCESS Newswire

Mar 09, 2025

Mar 08, 2025

Soligenix, Inc. (NASDAQ:SNGX) Sees Large Decrease in Short Interest - Defense World

Mar 08, 2025

Mar 06, 2025

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March - Yahoo Finance

Mar 06, 2025

Mar 06, 2025

Soligenix (SNGX) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 06, 2025

Mar 06, 2025

BiomednewsbreaksSoligenix Inc. (SNGX) To Present Hybrytetm And SGX302 Data At Dermatology Conferences - MENAFN.COM

Mar 06, 2025

Feb 28, 2025

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

Feb 28, 2025

Feb 26, 2025

Soligenix Aims To Push The Boundaries In Treating Rare Diseases - The Globe and Mail

Feb 26, 2025